Rubella Seroprevalence Boost in the Pediatric and Adolescent Population of Florence (Italy) as a Preventive Strategy for Congenital Rubella Syndrome (CRS)

Vaccines (Basel). 2020 Oct 12;8(4):599. doi: 10.3390/vaccines8040599.

Abstract

Background: Despite the availability of an effective vaccine since the 1970s, rubella disease and, importantly, congenital rubella syndrome (CRS) remain a public health concern. The aim of this study was to analyze the rubella seroprevalence in the children population of the province of Florence and compare the obtained results to a previous survey conducted in 2005-2006.

Methods: A qualitative measurement of anti-rubella antibodies was performed on 165 sera using the enzyme-linked immunosorbent Assay (ELISA). The anamnestic and vaccination status was also collected.

Results: Our study highlighted a very high rubella seroprevalence (85-100%) in our enrolled population. In the vaccinated group (153/165), 98.7% of them were positive to rubella antibodies.

Conclusions: Our study showed the highest seroprevalence rate reached in the province of Florence for rubella in the last 15 years, thanks to the several successful vaccination campaigns promoted in the Tuscany region. Our findings in pediatric and adolescent subjects are a key factor in preventing CRS in adult life, specifically in childbearing women. Thus, the set goal will be to keep the awareness about the vaccination for this preventable disease high.

Keywords: CRS; Florence; Italy; MMRV vaccination; adolescent; elimination; pediatric; rubella; seroprevalence; vaccination coverage.